{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:21:06Z","timestamp":1790803266100,"version":"4.1.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"18","license":[{"start":{"date-parts":[[2020,11,24]],"date-time":"2020-11-24T00:00:00Z","timestamp":1606176000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,11,24]],"date-time":"2020-11-24T00:00:00Z","timestamp":1606176000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s40265-020-01438-1","type":"journal-article","created":{"date-parts":[[2020,11,24]],"date-time":"2020-11-24T14:03:54Z","timestamp":1606226634000},"page":"1981-1986","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Sofpironium Bromide: First Approval"],"prefix":"10.1007","volume":"80","author":[{"given":"Julia","family":"Paik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,24]]},"reference":[{"key":"1438_CR1","doi-asserted-by":"crossref","unstructured":"Shargall Y, Spratt E, Zeldin RA. Hyperhidrosis: what is it and why does it occur? Thorac Surg Clin. 2008;18(2):125\u201332, v.","DOI":"10.1016\/j.thorsurg.2008.01.001"},{"issue":"1","key":"1438_CR2","first-page":"25","volume":"37","author":"M Amir","year":"2000","unstructured":"Amir M, Arish A, Weinstein Y, et al. Impairment in quality of life among patients seeking surgery for hyperhidrosis (excessive sweating): preliminary results. Isr J Psychiatry Relat Sci. 2000;37(1):25\u201331.","journal-title":"Isr J Psychiatry Relat Sci"},{"issue":"1","key":"1438_CR3","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/S0149-2918(03)90041-5","volume":"25","author":"A Campanati","year":"2003","unstructured":"Campanati A, Penna L, Guzzo T, et al. Quality-of-life assessment in patients with hyperhidrosis before and after treatment with botulinum toxin: results of an open-label study. Clin Ther. 2003;25(1):298\u2013308.","journal-title":"Clin Ther"},{"issue":"8","key":"1438_CR4","first-page":"908","volume":"33","author":"N Solish","year":"2007","unstructured":"Solish N, Bertucci V, Dansereau A, et al. A comprehensive approach to the recognition, diagnosis, and severity-based treatment of focal hyperhidrosis: recommendations of the Canadian Hyperhidrosis Advisory Committee. Dermatol Surg. 2007;33(8):908\u201323.","journal-title":"Dermatol Surg"},{"key":"1438_CR5","unstructured":"Kaken Pharmaceutical. ECCLOCK\u00ae gel 5% approved in Japan for the treatment of primary axillary hyperhidrosis [media release]. 25 Sep 2020. http:\/\/www.kaken.co.jp\/."},{"key":"1438_CR6","unstructured":"Kaken Pharmaceutical. ECCLOCK gel 5%. 2020. https:\/\/pmda.go.jp. Accessed 4 Nov 2020."},{"key":"1438_CR7","unstructured":"Brickell Biotech. Brickell Biotech provides update on Bodor Labs complaint and funding agreement with NovaQuest [media release]. 30 Oct 2019. http:\/\/brickellbio.com."},{"key":"1438_CR8","unstructured":"Brickell Biotech. Brickell Biotech announces settlement of dispute with Bodor Labs and entry into equity funding agreements [media release]. 18 Feb 2020. http:\/\/brickellbio.com."},{"key":"1438_CR9","unstructured":"Brickell Biotech. Brickell Biotech, Inc. signs exclusive license and development agreement for BBI-4000 with Kaken Pharmaceutical Co., Ltd [media release]. 1 Apr 2015. http:\/\/brickellbio.com."},{"key":"1438_CR10","unstructured":"Brickell Biotech. Sofpironium bromide. 2020. https:\/\/brickellbio.com\/rd\/pipeline\/sofpironium-bromide\/. Accessed 4 Nov 2020."},{"key":"1438_CR11","unstructured":"Yokozeki H, Fujimoto T, Yorozuya T, et al. A phase 3, randomized, double-blinded, vehicle-controlled study to evaluate the safety and efficacy of topically applied sofpironium bromide gel, 5% in Japanese patients with primary axillary hyperhidrosis [abstract no. S027]. In: American Academy of Dermatology, Virtual Meeting Experience. 2020."},{"key":"1438_CR12","unstructured":"Brickell Biotech. Brickell Biotech announces positive phase 3 pivotal study results for sofpironium bromide in Japan released by development partner, Kaken Pharmaceutical [media release]. 15 Jun 2020. http:\/\/brickellbio.com."},{"issue":"6","key":"1438_CR13","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1016\/j.jaad.2020.02.016","volume":"82","author":"B Kirsch","year":"2020","unstructured":"Kirsch B, Smith S, Cohen J, et al. Efficacy and safety of topical sofpironium bromide gel for the treatment of axillary hyperhidrosis: a phase II, randomized, controlled, double-blinded trial. J Am Acad Dermatol. 2020;82(6):1321\u20137.","journal-title":"J Am Acad Dermatol"},{"key":"1438_CR14","unstructured":"Brickell Biotech. BBI-4000 (sofpironium bromide) demonstrates promising potential as a safe and effective first-line treatment for excessive underarm sweating [media release]. 7 Mar 2016. http:\/\/brickellbio.com."},{"key":"1438_CR15","unstructured":"Brickell Biotech. Brickell Biotech reports first quarter 2020 financial results and provides corporate update [media release]. 13 May 2020. http:\/\/brickellbio.com."},{"key":"1438_CR16","unstructured":"Brickell Biotech. Brickell Biotech reports second quarter 2020 financial results and provides corporate update [media release]. 12 Aug 2020. https:\/\/brickellbio.com\/."},{"key":"1438_CR17","unstructured":"Brickell Biotech. Brickell Biotech announces initiation of US phase 3 program evaluating sofpironium bromide gel, 15% for the treatment of primary axillary hyperhidrosis [media release]. 6 Oct 2020. https:\/\/brickellbio.com\/."},{"key":"1438_CR18","unstructured":"Brickell Biotech. Brickell Biotech reports fourth quarter and full year 2019 financial results and provides corporate update [media release]. 18 Mar 2020. http:\/\/brickellbio.com."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-020-01438-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-020-01438-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-020-01438-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T14:55:55Z","timestamp":1606834555000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-020-01438-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,24]]},"references-count":18,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1438"],"URL":"https:\/\/doi.org\/10.1007\/s40265-020-01438-1","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,24]]},"assertion":[{"value":"24 November 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Julia Paik is a salaried employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}